Observational Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Aug 15, 2025; 17(8): 105818
Published online Aug 15, 2025. doi: 10.4251/wjgo.v17.i8.105818
Contrast-enhanced ultrasound in evaluating the curative effect of interventional therapy in patients with liver cancer
Li-Ping Chen, Yan Dong, Jing-Guang He, Qing-Qing Yang, Zhi-Wen Hu
Li-Ping Chen, Yan Dong, Jing-Guang He, Zhi-Wen Hu, Department of Medical Ultrasound, Guangzhou First People's Hospital, Guangzhou 510180, Guangdong Province, China
Qing-Qing Yang, Department of Medical Ultrasound, The Second People’s Hospital of Baiyun, Guangzhou 510450, Guangdong Province, China
Co-first authors: Li-Ping Chen and Yan Dong.
Author contributions: Chen LP drafted the initial draft; Chen LP and Dong Y drafted the initial draft, contributed to the formal analysis as the co-first authors of the paper; Chen LP and Hu ZW participated in data collection and the concept of study, guided the research, methodology, and visualization of the manuscript; Dong Y, He JG and Yang QQ contributed to the formal analysis of this study; Chen LP, Dong Y, He JG, Yang QQ, and Hu ZW participated in this study, validated it, and jointly reviewed and edited the manuscript; all of the authors read and approved the final version of the manuscript to be published.
Supported by Science and Technology Program of Guangzhou, No. 2024A03J1029; Science and Technology Program of Chinese Medicine and Integrated Chinese and Western Medicine in Guangzhou, No. 20252A010001.
Institutional review board statement: This research has been reviewed and approved by the Ethics Committee of Guangzhou First People's Hospital.
Informed consent statement: The informed consent forms signed by the patients were obtained in this study.
Conflict-of-interest statement: The authors of this study declare that there is no conflict of interest.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Data sharing statement: No available data.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhi-Wen Hu, MD, Department of Medical Ultrasound, Guangzhou First People's Hospital, No. 1 Panfu Road, Guangzhou 510180, Guangdong Province, China. charleyhu@163.com
Received: April 25, 2025
Revised: May 29, 2025
Accepted: July 1, 2025
Published online: August 15, 2025
Processing time: 110 Days and 22.8 Hours
Core Tip

Core Tip: This observational study highlights the value of contrast-enhanced ultrasonography (CEUS) in evaluating the therapeutic response of liver cancer patients to interventional therapy. CEUS enables real-time visualization of tumor perfusion patterns, microvessel density changes, and alterations in tumor markers. Among 124 patients, CEUS demonstrated high sensitivity (85.72%) and specificity (92.31%) in assessing treatment efficacy. Notably, tumor blood flow and tumor marker levels (alpha-fetoprotein, carcinoembryonic antigen, carbohydrate antigen 19-9) significantly decreased post-treatment. These findings support CEUS as a reliable, noninvasive tool for monitoring treatment outcomes and guiding clinical decision-making in liver cancer management.